Current Liabilities
Accounts payable and other current liabilities (Note 11)
Neurocrine Biosciences Accounts payable and other current liabilities (Note 11) increased by 14.6% to $773.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 62.7%, from $475.20M to $773.00M. Over 5 years (FY 2020 to FY 2025), Accounts payable and other current liabilities (Note 11) shows an upward trend with a 31.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2016
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase can signal improved cash management (extending payment terms) or higher operational activity, while a decrease may indicate faster payments to suppliers.
Detailed definition
This represents short-term obligations to suppliers for goods and services received, along with other accrued expenses....
Peer comparison
Standard metric for assessing working capital efficiency and trade credit usage across all industries.
Metric ID:
current_liabilities_accounts_payable_and_accrued_liabili_26f6ceHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $190.90M | $205.90M | $225.80M | $235.90M | $265.70M | $297.80M | $347.60M | $355.70M | $391.60M | $503.00M | $448.80M | $417.20M | $358.50M | $392.70M | $461.60M | $475.20M | $489.50M | $584.30M | $674.30M | $773.00M |
| QoQ Change | — | +7.9% | +9.7% | +4.5% | +12.6% | +12.1% | +16.7% | +2.3% | +10.1% | +28.4% | -10.8% | -7.0% | -14.1% | +9.5% | +17.5% | +2.9% | +3.0% | +19.4% | +15.4% | +14.6% |
| YoY Change | — | — | — | — | +39.2% | +44.6% | +53.9% | +50.8% | +47.4% | +68.9% | +29.1% | +17.3% | -8.5% | -21.9% | +2.9% | +13.9% | +36.5% | +48.8% | +46.1% | +62.7% |
Range$190.90M – $773.00M
CAGR+34.2%
Avg YoY Growth+33.2%
Median YoY Growth+41.9%
Current Streak7 quarters growth
Accounts payable and other current liabilities (Note 11) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's accounts payable and other current liabilities (note 11)?
- Neurocrine Biosciences (NBIX) reported accounts payable and other current liabilities (note 11) of $773.00M in Q1 2026.
- How has Neurocrine Biosciences's accounts payable and other current liabilities (note 11) changed year-over-year?
- Neurocrine Biosciences's accounts payable and other current liabilities (note 11) increased by 62.7% year-over-year, from $475.20M to $773.00M.
- What is the long-term trend for Neurocrine Biosciences's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's accounts payable and other current liabilities (note 11) has grown at a 31.9% compound annual growth rate (CAGR), from $168.70M to $674.30M.
- What does accounts payable and other current liabilities (note 11) mean?
- Short-term debts owed to suppliers and other accrued operational expenses.